AB0353 bDMARD CHOICES FOR INFLAMMATORY ARTHRITIS WITH CHRONIC KIDNEY DISEASE; HUR-BIO REAL-LIFE REGISTRY
Authors: G. Sandal Uzun, A. Taghiyeva, İ. Y. Çakir, K. Moral, E. Bilgin, G. K. Yardimci, B. Farisogullari, E. C. Bolek, E. Duran, Z. Özsoy, G. Ayan, M. Ekici, E. Unaldi, L. Kiliç, A. Akdoğan, O. Karadag, Ş. A. Bilgen, S. Kiraz, A. İ. Ertenli, U. Kalyoncu
Journal: Annals of the Rheumatic Diseases (2022)

Background Rheumatic disesases may involve multiple systems and chronic kidney disease (CKD) can be seen during the course of diseases. Accompanying CKD affects the the choice of treatments in patients with rheumatic disease. There is limited data on the use of biological DMARDs in rheumatic patients with chronic kidney disease. Objectives To determine the preferred first and second bDMARDs in patients in the CKD in the bDMARD cohort. Methods The Hacettepe University biological database (HUR-BIO), was established in 2005. A total of 2160 RA patients, 3744 SPA patients, were registered in HUR-BIO until November 2021. The CKD was confirmed and classified according to 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines. . Patients were evaluated for the presence of CKB before the initiation of bDmard and during follow-up under bDMARDs. Age and sex matched RA patients without CKD were selected for the control group. Results 142/5904 (2.4%) patients have CKD. 102(%71.8) patients had CKD prior to initiation of bDMARD and 40 (28.1%) patients had developed during follow-up. The median time to CKD development after starting bDMARD was 4.13 years(±4.05). Of the patients with CKD, 98 (69.0%) had RA and 44 (31.0%) had SpA. RA patients followed for CKD were older than SpA (66.0 (±11.1) vs 59.1 (±13.0) years, p=0.001), female gender was more common (73.5% vs 36.4%, p&lt;0.001), disease duration was similar (19.3 (±13.8) vs 17.1 (±10.5) years, p=0.40). The first bDMARD choices of patients with and without CKD in RA and SpA patients were shown in Table 1. There was no difference between the SPA patients with or without CKD regarding TNF-i preferences. In patients with rheumatoid arthritis there was no difference in terms of TNFi and non-TNF-i preferences, but tocilizumab was more prefered in CKD group. Table 1. Relationship between remission according to bDMARD and CKD Rheumatoid arthritis p Spondyloarthritis p w CKD n=98 wo CKD n=91 w CKD n=44(%) wo CKD n=80(%) p&lt;0,05 Etanercept, n(%) 34 (34.6) 30 (33.0) 0.46 17 (38.6) 22 (27.5) P=0.14 Adalimumab, n(%) 17(17.3) 17 (18.7) 0,48 10 (22.7) 22 (27.5) P=0.36 Infliximab,n(%) 3 (3) 8 (8.8) 0.85 14(31.8) 32 (40.0) p=0.24 Golimumab, n(%) 4 (4) 3 (3.3) 0,54 1 (2.2) 3 (3.8) p=0.55 Certolizumab, n(%) 0 (0) 3 (3.3) 0,11 1 (2.2) 1 (1.3) p=0.58 Anti-TNF therapy, n(%) 58 (59.2) 61 (67.0) 0,61 43 80 0.352 Non-TNF biologics, n(%) 40 (40,8) 30 (33.0) 0,13 1 0 0.355 Rituximab, n(%) 14 (14.3) 12 (13.2) 0,57 Abatacept, n(%) 14(14.3) 12 (13.2) 0,49 Tocilizumab, n(% ) 6 (6.1 ) 1 0.041 1(2.2) p=0.35 Jak-kinase inhibitors, n(%) 6(6.1) 5 (5.5) 0.55 Conclusion In our biologic cohort, 2% of patients with RA and SpA had accompanying CKD. In one-third of the patients with CKD, it was developed during the follow-up after bDMARDs. In patients with RA, there was no difference in terms of TNFi and non-TNF-i preferences. It should be kept in mind that CKD may develop during the follow-up of patients using bDMARDs. References [1]Ye W, Zhuang J, Yu Yet all Gender and chronic kidney disease in ankylosing spondylitis: a single-center retrospectively study. BMC Nephrol. 2019 Dec 9;20 [2]Chebotareva NV, Guliaev SVet al. [Chronic kidney disease in rheumatoid arthritis patients: prevalence, risks factors, histopathological variants]. Ter Arkh. 2019 May 15;91(5) Disclosure of Interests None declared